Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963766 · ClinicalTrials.gov registry record · Phase 3
A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 154
- Enrollment target
NCT02963766: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02963766 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 154 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02963766, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 154 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.
Primary Outcome
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean in HbA1c was calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) and adjusted by, baseline + insulin Use + metformin Use + treatment + time + treatment\*time (Type III sum of squares). Variance-covariance structure = unstructured (for actual value) / unstructured (for change
Interventions
- DRUG Placebo
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2016-12-29 |
| Est. Completion | 2022-01-12 |
| Phase | Phase 3 |
What the finished NCT02963766 record still lists
NCT02963766 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02963766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02963766 about?
NCT02963766 is a clinical study titled "A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes". The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.
What is the current status of trial NCT02963766?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 154 participants. The study started on 2016-12-29. Estimated completion is 2022-01-12.
What interventions are being tested in trial NCT02963766?
The interventions under investigation include: Placebo (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT02963766?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02963766's enrollment target sits among peer trials
154 1509th of 2000 higher than 491 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI